Fact Sheet for Healthcare Providers: Babson Diagnostics aC19G1, Babson Diagnostics, Inc. | NLM

Disaster Information Management Research Center | NLM

Fact Sheet for Healthcare Providers: Babson Diagnostics aC19G1, Babson Diagnostics, Inc.

06/23/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 6/23/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Babson Diagnostics aC19G1 test. The Babson Diagnostics aC19G1 test is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (potassium EDTA, lithium heparin). (PDF)